Article thumbnail

Targeted Secretion Inhibitors—Innovative Protein Therapeutics

By Keith Foster and John Chaddock

Abstract

Botulinum neurotoxins are highly effective therapeutic products. Their therapeutic success results from highly specific and potent inhibition of neurotransmitter release with a duration of action measured in months. These same properties, however, make the botulinum neurotoxins the most potent acute lethal toxins known. Their toxicity and restricted target cell activity severely limits their clinical utility. Understanding the structure-function relationship of the neurotoxins has enabled the development of recombinant proteins selectively incorporating specific aspects of their pharmacology. The resulting proteins are not neurotoxins, but a new class of biopharmaceuticals, Targeted Secretion Inhibitors (TSI), suitable for the treatment of a wide range of diseases where secretion plays a major role. TSI proteins inhibit secretion for a prolonged period following a single application, making them particularly suited to the treatment of chronic diseases. A TSI for the treatment of chronic pain is in clinical development

Topics: Review
Publisher: MDPI
OAI identifier: oai:pubmedcentral.nih.gov:3153183
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2000). A conjugate composed of nerve growth factor coupled to a non-toxic derivative of Clostridium botulinum neurotoxin type A can inhibit neurotransmitter release in vitro. Growth Factor
  2. A study of the safety and efficacy of AGN-214868 in patients with postherpetic neuralgia.
  3. (2009). Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with antinociceptive potential.
  4. (2009). Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): Report of the therapeutic and technology assessment subcommittee of the American Academy of Neurology. Neurology
  5. (2008). Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology
  6. (2008). Biology and clinical pharmacology of botulinum neurotoxin type C and other non-A/ non-B botulinum neurotoxins.
  7. (2007). BoNT receptor binding identification of the protein receptor binding site of botulinum neurotoxins B and G drives the double-receptor concept.
  8. (2006). Botulinum neurotoxin – from laboratory to bedside.
  9. (1997). Botulinum neurotoxin B inhibits insulin-stimulated glucose uptake into 3T3-L1 adipocytes and cleaves cellubrevin unlike type A toxin which failed to proteolyze the SNAP-23 present. Biochemistry
  10. (2008). Botulinum neurotoxin for dermatologic and cosmetic disorders. In Botulinum Toxin Therapeutic Clinical Practice
  11. (2007). Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain. PloS Pathog.
  12. (2010). Botulinum neurotoxin: A marvel of protein design.
  13. Botulinum neurotoxins in the treatment of refractory pain.
  14. (2001). Botulinum toxin as a biological weapon medical and public health management. JAMA
  15. (2008). Botulinum toxin drugs: Future developments.
  16. (2004). Botulinum toxin in clinical practice.
  17. (1999). Botulinum toxin in the treatment of neurological disorders of the autonomic nervous system.
  18. (1980). Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery.
  19. (1980). Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Opthalmology
  20. (2008). Botulinum toxin products overview. Skin Ther.
  21. (2008). Botulinum toxin therapy in gastrointestinal disorders.
  22. (2000). Capsaicin stimulates release of substance P from dorsal root ganglion neurons via two distinct mechanisms.
  23. (2009). Catalytic properties of botulinum neurotoxin subtypes A3 and A4. Biochemistry
  24. (2005). Clin Infect. Dis.
  25. (2008). Clinical experience and recent advances in the management of gait disorders with botulinum neurotoxin.
  26. (2008). Clinical trials of botulinum toxin in adult spasticity.
  27. (2006). Clinical use of non-A botulinum toxins: Botulinum toxin type C and botulinum toxin type
  28. (2006). Clostridial neurotoxins: Structure-function led design of new therapeutics. Cell Mol. Life Sci.
  29. (2008). Comparative clinical trials of botulinum neurotoxins.
  30. (2003). Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology
  31. (1995). Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm. Neurology
  32. (1991). Cooperative action of the light chain of tetanus toxin and the heavy chain of botulinum toxin type A on the transmitter release of mammalian motor endplates.
  33. (2009). Crystal structure of a catalytically active, non-toxic endopeptidase derivative of Clostridium botulinum toxin
  34. (2005). Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibres following intradetrusor injections of botulinum toxin for human detrusor
  35. (2009). Development of future indications for BOTOX ®. Toxicon
  36. (1994). Differences in the protease activities of tetanus and botulinum B toxins revealed by the cleavage of vesicle-associated membrane protein and various sized fragments. Biochemistry
  37. (1998). Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans.
  38. (2004). Different types of botulinum toxin in humans.
  39. (2009). Disease-oriented approach to botulinum toxin use. Toxicon
  40. (2009). Domain organization in Clostridium botulinum neurotoxin type E is unique: Its implication in faster translocation.
  41. (2010). efficacy study of AGN-214868 in patients with idiopathic overactive bladder and urinary incontinence.
  42. (2009). Engineered toxins: New therapeutics. Toxicon
  43. (2009). Engineering botulinum neurotoxins to extend therapeutic intervention.
  44. (2003). Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache
  45. (2007). Expanding clinical uses of botulinum neurotoxins. In Treatments from Toxins;
  46. (2008). Experience with A2NTX in dystonia and spasticity. Toxicon
  47. (2002). Expression and purification of catalytically active, non toxic endopeptidase derivatives of Clostridium botulinum toxin type A. Protein Exp. Purif.
  48. (2007). From poison to remedy: The chequered history of botulinum toxin.
  49. (2008). Future aspects of botulinum neurotoxins.
  50. (2007). Genetic diversity among botulinum neurotoxin-producing clostridial strains.
  51. (2009). Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F. Biochemistry
  52. (2008). Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons.
  53. (2006). Harnessing Toxins.
  54. (1998). History of the cosmetic use of botulinum A exotoxin.
  55. (1986). How do tetanus and botulinum toxins bind to neuronal membranes? Trends Biochem. Sci.
  56. (1996). Identification of a novel syntaxin- and synaptobrevin/ VAMP-binding protein, SNAP-23, expressed in non-neuronal tissues.
  57. (2004). Identification of the major steps in botulinum toxin action.
  58. (1962). Influence of nerve-ending activity and of drugs on the rate of paralysis of rat diaphragm preparations by Cl. botulinum type A
  59. (2002). Inhibition of release of Toxins 2010, 2 neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin.
  60. (2000). Inhibition of vesicular secretion both neuronal and nonneuronal cells by a retargeted endopeptidase derivative of Clostridium botulinum neurotoxin type
  61. (2008). Intragastric injection of botulinum toxin for the treatment of obesity. Where are we? World
  62. (2007). Introduction to clinical use of botulinum neurotoxins. In Treatments from Toxins;
  63. (1984). Investigation of the mode of action of tetanus toxin with the acid of hybrid molecules consisting in part of tetanus toxin-derived fragments.
  64. (1980). Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction.
  65. (2007). Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons.
  66. (2007). Mechanism of substrate recognition by botulinum neurotoxin serotype
  67. (2008). Membrane interaction of botulinum neurotoxin A translocation (T) domain: The belt region is a regulatory loop for membrane interaction.
  68. (2008). Molecular architecture of botulinum neurotoxin E revealed by single particle electron microscopy.
  69. (2009). Neurobloc ®/Myobloc ®: Unique features and findings. Toxicon
  70. (2000). Neurotoxins affecting neuroexocytosis.
  71. (2008). Novel Chimeras of botulinum neurotoxin A and E unveil contributions from the binding, translocation and protease domains to their functional characteristics.
  72. (2010). OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache
  73. (1997). Peptide that mimics the C-terminal sequence of SNAP-25 inhibits secretory vesicle docking in chromaffin cells.
  74. (1999). Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett.
  75. (2005). Preparation of specifically activatable endopeptidase derivatives of Clostridium botulinum toxins type A, B and C and their applications.
  76. (2006). Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity.
  77. (1999). Proteolysis of SNAP-25 isoforms by botulinum neurotoxin types A, C, and E: Domains and amino acid residues controlling the formation of enzyme-substrate complexes
  78. (1995). Proteolysis of synthetic peptides by type A botulinum neurotoxin.
  79. (1981). purification and toxoiding of clostridium botulinum A toxin.
  80. (2010). Re-engineering clostridial neurotoxins for the treatment of chronic pain: Current status and future prospects.
  81. (2008). Reconstituted membrane fusion requires regulatory lipids, SNAREs and synergistic SNARE chaperones.
  82. (2009). Reconstitution of Rab- and SNARE-dependent membrane fusion by synthetic endosomes.
  83. (2006). Recovery from botulinum neurotoxin poisoning in vivo. Neuroscience
  84. (2004). Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity.
  85. (2004). Retargeted clostridial endopeptidases: Inhibition of nociceptive neurotransmitter release in vitro and antinociceptive activity in in vivo models of pain.
  86. (2000). Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon
  87. (1993). SNAP receptors implicated in vesicle targeting and fusion. Nature
  88. (2005). SNAREs and traffic.
  89. (2006). SNAREs—Engines for membrane fusion. Nature Rev.
  90. (2000). Spectroscopic analysis of pH-induced changes in the molecular features of type A botulinum neurotoxin light chain. Biochemistry
  91. (2010). Structure and activity of a functional derivative of Clostridium botulinum neurotoxin
  92. (1998). Structure of botulinum neurotoxin type A and implications for toxicity.
  93. (2004). Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain
  94. (2004). Substrate recognition strategy for botulinum neurotoxin serotype A. Nature
  95. (2006). SV2 is the protein receptor for botulinum neurotoxin A. Science
  96. (2004). Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin
  97. (2003). Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells.
  98. (1986). Tetanus toxin in dissociated spinal cord cultures: long-term characterization of form and
  99. (1998). The 26-mer peptide released from SNAP-25 cleavage by botulinum neurotoxin E inhibits vesicle docking. FEBS Lett.
  100. (2002). The changed image of botulinum toxin: Its unlicensed use is increasing dramatically, ahead of robust
  101. (2004). The HCC-domain of botulinum neurotoxin A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction.
  102. (1996). The high affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a. FEBS Lett.
  103. (2004). The mechanisms of vesicle budding and fusion. Cell
  104. (2008). The use of endopep-MS to detect multiple subtypes of botulinum neurotoxins
  105. (1997). The variability in the clinical effect induced by botulinum toxin type A: The role of muscle activity in humans.
  106. (2003). Translocation of botulinum neurotoxin light chain protease through the heavy chain channel.
  107. (2005). Transport protein which is used to introduce chemical compounds into nerve cells.
  108. (1992). Treatment of glabellar frown lines with C. botulinum-A exotoxin.
  109. (2008). Treatment of motor disorders in cerebral palsy with botulinum neurotoxin.
  110. (2004). Uptake of botulinum neurotoxin into cultured neurons. Biochemistry
  111. (2003). What is the role of SNARE proteins in membrane fusion?
  112. (2009). Xeomin is free from complexing proteins. Toxicon